ImmunoGen Financial News

Bharat Biotech International Ltd on Sunday said it started clinical trials of the Tuberculosis vaccine Mtbvac on adults in India. This is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri, a press release from Bharat Biotech said. The release said that Mtbvac is being developed for two purposes; firstly, as a more effective and potentially longer-lasting vaccine than BCG ( Bacillus Calmette Guerin) for newborns and secondly, for the prevention of TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are carried out by Bharat Biotech in close collaboration with Biofabri. Trials to evaluate the safety and immunogenicity of Mtbvac have started with a pivotal safety, immunogenicity and efficacy trial which has been planned to start in 2025, the release said. It is a giant step to test in adults and adolescents in the country where 28 per cent of the world's TB cases accumulate.

Bharat Biotech International Ltd on Sunday said it has started clinical trials of tuberculosis vaccine candidate MTBVAC in India. The only vaccine in use today--BCG (Bacillus Calmette and Guerin)--is an attenuated variant of the bovine TB pathogen. This is more than a hundred years old and has a limited effect on pulmonary tuberculosis, which is mostly responsible for the transmission of the disease. Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine," the company said. The trials have been done in collaboration with Spanish biopharmaceuticals company Biofabri to evaluate the safety, immunogenicity and efficacy of MTBVAC in India. «MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for new-borns, and for the prevention of TB disease in adults and adolescents, for whom there is currently no effective vaccine,» Bharat Biotech International said. MTBVAC, the Spanish tuberculosis vaccine, is the first live attenuated vaccine of mycobacterium tuberculosis isolated from a human.

(Reuters) — AbbVie (NYSE:ABBV) is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen (NASDAQ:IMGN) and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.

how to do it in a manner that could make them a staple of cancer care. That’s reflected in pharma companies’ sudden deep commitment to the space. In addition to AbbVie’s acquisition, other deals this year include Pfizer’s proposed $43 billion buyout of Seagen, Merck & Co’s $4 billion tie-up with Daiichi Sankyo, and a series of smaller investments from Bristol-Myers Squibb and Eli Lilly & Company.

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.

Investing.com — U.S. futures traded higher Thursday, ahead of the release of key inflation data which could guide future Federal Reserve interest rate decisions.

(Reuters) -AbbVie said on Thursday it will buy drugmaker ImmunoGen (NASDAQ:IMGN) for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Tesla, CVS, ImmunoGen, and Etsy, and a downgrade for DoorDash.